Neoantigen vaccinebreast cancer The dominant search intent for "neoantigen peptide vaccine" is to understand what it is, how it works, and its current status in cancer treatment. This includes its personalized nature, the use of peptides derived from tumor mutations, and its application in clinical trials.
Tier 1 Entities & Phrases:
* neoantigen peptide vaccine
* neoantigen
* peptide
* vaccine
* personalized
* cancer
* tumor
* immune cells
* T-cell responses
Tier 2 Entities & Phrases:
* synthetic long peptides
* mutations
* drug combinations (e.g., with pembrolizumab, tislelizumab)
* clinical trials
* advanced solid tumors
* melanoma, GBM, NSCLC, CRC, pancreatic cancer, multiple myeloma, breast cancer
* immunogenicity
* efficacy and safety
* patient-specific antigens
Tier 3 Entities & Phrases:
* repetitive terms (e作者：Z Chen·2021·被引用次数：78—Aneoantigen-basedpeptide vaccinefor patients with advanced pancreatic cancer refractory to standard treatment..gPersonalized Neoantigen Vaccines for Aggressive Cancers., multiple mentions of "vaccine," "peptide," "neoantigen" without adding new information)
* overly specific trial names or identifiers unless they illustrate a broader point
* commercial mentions unless they represent a unique service (e作者：X Li·2024·被引用次数：55—Neoantigen peptide vaccinesare comprised of small chains of amino acids that correspond to specific neoantigens identified in a tumor. These ....g., "one-stop-shop")
---
A neoantigen peptide vaccine represents a cutting-edge frontier in cancer treatment, leveraging the unique characteristics of an individual's tumor to stimulate a targeted immune response. These vaccines are designed to harness the power of the patient's own immune system by identifying and presenting specific "neoantigens"—abnormal peptides arising from DNA mutations within tumor cells—to immune cellsApeptide-based cancervaccineconsisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential .... The goal is to train the immune system, particularly T-cells, to recognize and eliminate cancer cells that display these unique markers, offering a highly personalized and potentially more effective therapeutic strategy than traditional treatments.
At its core, a neoantigen peptide vaccine is a therapeutic agent composed of short chains of amino acids, or peptides, that precisely match the neoantigens detected in a patient's tumor. Unlike normal cellular proteins, neoantigens are immunogenic and unique to the tumor, making them ideal targets for a cancer-specific immune attackApeptide-based cancervaccineconsisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential .... The process typically involves sequencing a patient's tumor to identify these specific mutations and then synthesizing corresponding peptides.2024年9月11日—This phase I trial studies the safety of personalizedneo-antigen peptide vaccinein treating patients with stage IIIC-IV melanoma or hormone ... These synthetic peptides are then administered as a vaccine, aiming to elicit robust T-cell responses against the tumor.
The highly personalized nature of neoantigen peptide vaccines is a key differentiator. Each patient's cancer carries a unique set of mutations, leading to a distinct profile of neoantigens.2024年9月11日—This phase I trial studies the safety of personalizedneo-antigen peptide vaccinein treating patients with stage IIIC-IV melanoma or hormone ... This means that a neoantigen peptide vaccine is not a one-size-fits-all solution but is custom-designed for each individual. This bespoke approach aims to maximize efficacy by targeting the precise molecular alterations driving the patient's specific cancer, a significant advancement in precision medicine2025年4月2日—Mechanistically,peptide vaccinesare designed to induce humoral and cell-mediated anti-tumor immune responses. Vaccines may consist of .... Technologies like synthetic long peptides are explored to enhance the immunogenicity and effectiveness of these personalized vaccines.A phase I pilot study of personalized neoantigen peptide ...
The mechanism of action for a neoantigen peptide vaccine involves several critical steps. First, tumor sequencing identifies neoantigens. Second, corresponding peptides are synthesized, often as synthetic long peptides to better engage the immune systemNeoantigen-based mRNA vaccine exhibits superior anti .... Third, these peptides are administered to the patient, typically with adjuvants to boost the immune response.Personalized Neoantigen Peptide Vaccine with or without ... The presented peptides are then recognized by antigen-presenting cells, which in turn activate T-cells. These activated T-cells can then infiltrate the tumor and induce an anti-tumor immune response, leading to tumor cell death.2024年11月5日—PersonalizedNeoantigen Peptide Vaccinewith or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma ( ... This process aims to generate both cellular and humoral immune responses.
Neoantigen peptide vaccines are showing considerable promise in clinical trials across various advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), glioblastoma (GBM), colorectal cancer (CRC), and pancreatic cancer作者：E Blass·2025·被引用次数：14—Personalizedneoantigen-targetingvaccineshave demonstrated great promise; however, improved immunogenicity is still needed. Since antigen .... Early-stage studies have demonstrated their safety and feasibility, with some trials reporting encouraging signs of efficacy, such as preventing recurrence and improving survival rates. For instance, studies combining neoantigen peptide vaccines with other immunotherapies like pembrolizumab or tislelizumab are being investigated to enhance treatment outcomes.作者：E Blass·2025·被引用次数：14—Personalizedneoantigen-targetingvaccineshave demonstrated great promise; however, improved immunogenicity is still needed. Since antigen ... Research is also exploring their potential in hematological malignancies, such as smoldering multiple myeloma.
Despite the excitement surrounding neoantigen peptide vaccines, challenges remain2025年4月2日—Mechanistically,peptide vaccinesare designed to induce humoral and cell-mediated anti-tumor immune responses. Vaccines may consist of .... Improving immunogenicity is an ongoing area of research, as is optimizing the vaccine design and delivery platforms.Neoantigen Peptide Cancer Vaccine Trials Identifying the most effective neoantigens and understanding factors like neoantigen load are crucial for maximizing therapeutic benefit. Furthermore, the complexity and cost associated with personalized vaccine development require efficient manufacturing and logistical processes. Continued research and clinical trials are essential to refine these therapies, expand their application to a broader range of cancers, and ultimately establish their role as a standard treatment option in oncology.
Join the newsletter to receive news, updates, new products and freebies in your inbox.